Most importantly, the randomized, placebo-controlled phase III trial ECHELON-2 confirmed that front-line treatment with BV and cyclophosphamide, doxorubicin, and prednisone (CHP) was superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for patients with CD30-positive PTCL [7]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.